美国ImmuNext


ImmuNext is dedicated to developing novel therapeutics that modulate the immune system to treat cancer and autoimmune diseases. Our founder, from the Geisel School of Medicine at Dartmouth, has identified a number of immuno-regulatory targets and related drug candidates. The lead program is based on a proprietary checkpoint regulator in the B7 family.
We are located in Lebanon, NH, with a great combination of intellectual and cultural stimulation from Dartmouth College and the beauty of rural New England.